Gene · 104
ADARB1: adenosine deaminase RNA specific B1
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. ADARB1: adenosine deaminase RNA specific B1. Genes, record 104. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/104
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P78563 | Double-stranded RNA-specific editase 1 | 741 | 13 | Ensembl, GeneID, HGNC |
Source UniProt
Patents55
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| US 12601751 B2 | 2026-04-14 | 9 | P78563 | Espacenet |
| EP 4720289 A1 | 2026-04-08 | 207 | P78563 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 36641 | P78563 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 36645 | P78563 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 36646 | P78563 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 7816 | P78563 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 7903 | P78563 | Espacenet |
| EP 4608979 A1 | 2025-09-03 | 876 | P78563 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 7903 | P78563 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 7816 | P78563 | Espacenet |
1 to 10 of 55
See all 55 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,355
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | ADARB1 papers | Newest fiscal year |
|---|---|---|---|
| P30CA010815 | Consolidated Basic Cancer Research Program | 18 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 11 | 2025 |
| P30CA042014 | Cancer Center Support Grant | 9 | 2025 |
| R35GM141907 | Defining and Controlling Protein-RNA interactions in editing and interference pathways | 7 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 5 | 2025 |
| K12GM068524 | San Diego IRACDA Scholars Program | 4 | 2025 |
| P30CA016058 | Cancer Center Support Grant | 4 | 2025 |
| T32CA009171 | Training Program in Basic Cancer Research | 4 | 2025 |
| P30CA015083 | Mayo Clinic Comprehensive Cancer Center Support Grant | 3 | 2025 |
| P30CA051008 | Georgetown University Lombardi Comprehensive Cancer Center Support Grant | 3 | 2025 |
1 to 10 of 1,355Source NIH's project files
See all 1,355 nih grantsPapers2,137
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| ADAR1 and ADAR2 Expression in the Thoracic Aortic Wall Correlates with Aneurysm Severity and Dissection Risk: Insights into A-to-I RNA Editing Dysregulation in Marfan Syndrome-Derived vSMCs. | Int J Mol Sci | 2026 | 42794678 | PubTator, text mining | PubMed |
| Dynamic reprogramming and A-to-I RNA editing in neutrophils in response to tumor induction. | J Biol Chem | 2026 | 42754162 | PubTator, text mining | PubMed |
| Context-dependent modulation of the TAK1-MAPK axis by ginsenoside-based formulations along the NAFLD-HCC continuum. | J Ginseng Res | 2026 | 42718885 | PubTator, text mining | PubMed |
| A-to-I editing modifies the target and role of miR-376a-3p in papillary thyroid cancer. | 3 Biotech | 2026 | 42688527 | PubTator, text mining | PubMed |
| ADAR-mediated RNA editing in CNS disorders: from pathogenic mechanisms to therapeutic opportunities. | Cell Mol Biol Lett | 2026 | 42576199 | PubTator, text mining | PubMed |
| New insight into RNA biomarkers in neuropathic pain: a clinician-neuroscientist roadmap to translational testing and treatment monitoring a clinical review. | Front Pain Res (Lausanne) | 2026 | 42534835 | PubTator, text mining | PubMed |
| A contextual activity score (CAS) for inferring ADAR-associated transcriptional activity across RNA-seq, single-cell, and spatial transcriptomics. | Comput Methods Programs Biomed | 2026 | 42526067 | PubTator, text mining | PubMed |
| A reduction in A-to-I RNA editing by ADAR disrupts Pumilio-mediated inhibition of MAPK signaling to drive intestinal stem cell aging. | Sci Signal | 2026 | 42520108 | PubTator, text mining | PubMed |
| ADAR2-Mediated RNA Editing Promotes TDP-43 Nuclear Export and Alters RNA Binding. | bioRxiv | 2026 | 42395430 | PubTator, text mining | PubMed |
| The regulatory mechanism and clinical significance of RNA editing in prostate cancer. | Curr Urol | 2026 | 42368672 | PubTator, text mining | PubMed |
1 to 10 of 2,137
See all 2,137 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/104
GET https://conductscience.org/api/genes/v1/104/patents?page=2